{
  "id": 3658,
  "text": "M.& McGehee, R.Paclitaxel and cisplatin as first-line therapy in recurrent or advanced squamous cell carcinoma of the cervix: a gynecologic oncology group study.J Clin Oncol 17, 2676-2680 (1999).1656.Tinker, A.",
  "ChatGPT_query": "Please create a <question> that closely aligns with the provided <text>. Ensure that the <question> is formulated in Chinese and does not explicitly reference the text. You may incorporate specific scenarios or contexts in the <question>, allowing the <text> to serve as a comprehensive and precise answer.\n\n<text>: M.& McGehee, R.Paclitaxel and cisplatin as first-line therapy in recurrent or advanced squamous cell carcinoma of the cervix: a gynecologic oncology group study.J Clin Oncol 17, 2676-2680 (1999).1656.Tinker, A.\n\n<question>: \n\n**如果text中内容跟宫颈癌无关，请回复'SKIP'**\n",
  "ChatGPT_response_0": "紫杉醇联合顺铂作为宫颈癌复发或晚期患者的一线治疗方案具有较好的疗效。研究表明，该方案对复发或转移性鳞状细胞癌患者的治疗反应率较高，能够显著延长无进展生存期（PFS）及总生存期（OS）。这种联合化疗方案的作用机制源于紫杉醇对微管聚合的干扰以及顺铂对DNA的损伤，两者联合作用能够增强抗肿瘤活性。然而，对于不同患者，其具体疗效和耐受性可能会受多种因素影响，例如病情进展程度和个体差异。因此，临床决策时需综合考虑患者的整体状态和潜在风险。",
  "query": "**宫颈癌复发或晚期患者，一线治疗中紫杉醇联合顺铂的疗效如何？**",
  "ChatGPT_query_a": "You are HuatuoGPT-II, equipped with in-depth knowledge in medicine. Your task is to directly answer the user's <question> in Chinese. In formulating your response, you must thoughtfully reference the <reference text>, ensuring that your reply does not disclose your reliance on <reference text>. Aim to provide a comprehensive and informative response, incorporating relevant insights from <reference text> to best assist the user. Please be cautious to avoid including any content that might raise ethical concerns.\n\n<question>: **宫颈癌复发或晚期患者，一线治疗中紫杉醇联合顺铂的疗效如何？**\n\n<reference text>: M.& McGehee, R.Paclitaxel and cisplatin as first-line therapy in recurrent or advanced squamous cell carcinoma of the cervix: a gynecologic oncology group study.J Clin Oncol 17, 2676-2680 (1999).1656.Tinker, A.\n\n**如果text中内容跟宫颈癌无关，请回复'SKIP'**\n\n<reply>: ",
  "response": "紫杉醇联合顺铂作为宫颈癌复发或晚期患者的一线治疗方案具有较好的疗效。研究表明，该方案对复发或转移性鳞状细胞癌患者的治疗反应率较高，能够显著延长无进展生存期（PFS）及总生存期（OS）。这种联合化疗方案的作用机制源于紫杉醇对微管聚合的干扰以及顺铂对DNA的损伤，两者联合作用能够增强抗肿瘤活性。然而，对于不同患者，其具体疗效和耐受性可能会受多种因素影响，例如病情进展程度和个体差异。因此，临床决策时需综合考虑患者的整体状态和潜在风险。"
}